secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oric Pharmaceuticals, Inc. (ORIC)
CIK:        0001796280
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0000950170-25-107313
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01, 2.05
LLM model:  deepseek-v4-flash:cloud@v2

ORIC Pharma restructures, cuts 20% workforce, and extends cash runway to 2H 2028
--------------------------------------------------------------------------------

- Initiated strategic pipeline prioritization, eliminating discovery research and reducing workforce by ~20%; expects ~$1.9M one-time charge in Q3 2025.
- Proforma cash and investments of $436.4M as of June 30, 2025, extending cash runway to 2H 2028 (previously 2H 2027).
- Q2 2025 R&D expenses $30.5M (up from $28.9M), G&A expenses $8.5M (up from $7.1M); no revenue reported.
- ORIC-944 Phase 1b data showed 59% PSA50 and 24% PSA90 responses; enozertinib (formerly ORIC-114) continues enrollment in NSCLC trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1796280/000095017025107313/0000950170-25-107313-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1796280/000095017025107313/oric-20250812.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-107313

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer